ClinicalTrials.gg
CompletedNCT01843556Updated Jun 18, 2023

A Phase 1 Study of E2022 Tape Formulation for Different Application Sites and Intervals in Japanese Healthy Elderly Males

A Phase 1 interventional study of E2022 Tape Formulation in Healthy Elderly Male, sponsored by Eisai Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by Eisai Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
65 Years and older
Sex
Male
01

Study summary

A phase 1 study of E2022 tape formulation in healthy elderly males to evaluate the safety and pharmacokinetics.

02

Conditions studied

  • Healthy Elderly Male
03

In context

Lead sponsor

Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male non-smokers (not smoking at least 4 weeks before Period 1) aged 65 years or older at
  2. at screening is 18.5 kg/m2 or above - below 28.0 kg/m2
  3. Written informed consent
  4. Given full explanation of this study and is willing to and able to comply with the protocol requirements

Exclusion criteria

Exclusion criteria:

  1. Have a current or past history of disorder requiring medical treatment within 8 weeks before the first application or infection within 4 weeks before the first application
  2. Have a disorder within 4 weeks before the first application which affects the evaluation of study drug such as psychiatric, gastrointestinal, hepatic, renal, respiratory, endocrinological, hematological, neurological or cardiovascular system, or congenital metabolic abnormality
  3. Have a history of gastrointestinal surgery (e.g., liver, kidney, digestive tract) which affects the pharmacokinetics of study drug,
  4. Have a history of treatment-requiring drug or food allergy or seasonal allergy at screening
  5. Had caffeine-containing food or drink or alcohol within 72 hours before study drug application in Period I
  6. Had nutritional supplements, herbal preparations (including oriental medicines) or others (e.g., grapefruit-containing food or beverage) which may affect drug metabolizing enzymes and transporters, within 1 weeks before Period I
  7. Have used liquid products (including cosmetics) on study application sites (back, upper limb, chest), patch, tape or bandage, within 4 weeks before Period 1
  8. Present or past clinical signs of skin to topical product or atopic dermatitis
  9. Excessively hairy or have shaved at application sites (back, upper limb, chest) within 4 weeks before Period 1
  10. Eczema, dermatitis, abnormal pigmentation, injury, or scar at application sites which may affect the evaluation of skin symptoms
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    E2022 Tape Formulation

    Drug: E2022 Tape Formulation

Interventions

  • E2022 tape formulation applied to different application sites and at different intervals in Japanese healthy elderly males

    Also known as: Donepezil

06

What researchers measure

Primary outcomes

  1. Number and frequency of adverse events

    Time frame: 168 hours after the end of application

Secondary outcomes

  1. Maximal Drug Concentration (CMax)

    Time frame: 216 hours after the end of application

  2. Area Under the Plasma Concentration-Time Curve (AUC)

    Time frame: 216 hours after the end of application

  3. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 216 hours after the end of application

  4. Plasma Decay Half-Life (t1/2)

    Time frame: 216 hours after the end of application

07

Study locations

1 site
  • Kagoshima, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Apr 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2013
First posted
Apr 30, 2013
Start
Dec 2012
Primary completionActual
Apr 2013
CompletionActual
Jun 2013
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01843556
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Apr 30, 2013
Start date
Dec 2012
Primary completion
Apr 2013
Completion
Jun 2013
Last update
Jun 18, 2023

Study contacts

Hidetaka Hiramatsu
study director · Eisai Co., Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion